1. Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1. (August 2018) Authors: Ray, K.; Stoekenbroek, R.M.; Kallend, D.; Leiter, L.A.; Landmesser, U.; Scott-Wright, R.; Wijngaard, P.; Kastelein, J.J.P. Journal: Atherosclerosis Issue: Volume 275(2018) Page Start: e9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Inclisiran Durably Lowers Ldl-C And Pcsk9 Expression In Subjects With Homozygous Familial Hypercholesterolaemia: The Orion-2 Pilot Study. (August 2019) Authors: Raal, F.; Lepor, N.; Kallend, D.; Stoekenbroek, R.; Wijngaard, P.; Hovingh, G.K. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy, Safety And Pharmacokinetics Of Inclisiran By Renal Function. (August 2019) Authors: Kallend, D.; Collins, M.; Kastelein, J.; Landmesser, U.; Leiter, L.; Ray, K.; Robson, R.; Stoekenbroek, R.; Wright, R.S.; Wijngaard, P. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Acute and prolonged changes in lipoprotein profile in human volunteers treated with single ascending doses of MDCO-216 (apoA1-MILANO/POPC). Issue 1 (July 2015) Authors: Kempen, H.; Asztalos, B.F.; Jeyarajah, E.; Otvos, J.; Gomaraschi, M.; Calabresi, L.; Kallend, D.; Bobillier, A.; Bellibas, S.; Wijngaard, P. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial. (December 2020) Authors: Ray, K.K.; Kallend, D.; Leiter, L.A.; Raal, F.J.; Koenig, W.; Jaros, M.J.; Schwartz, G.G.; Landmesser, U.; Wijngaard, P.L.; Wright, R.S.; Kastelein, J.J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia. (December 2020) Authors: Raal, F.J.; Kallend, D.; Ray, K.K.; Turner, T.A.; Koenig, W.; Wright, R.S.; Wijngaard, P.L.; Curcio, D.; Jaros, M.J.; Leiter, L.A.; Landmesser, U.; Kastelein, J.J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Acute and prolonged changes in lipoprotein profile in human volunteers treated with single ascending doses of MDCO-216 (apoA1-MILANO/POPC). Issue 1 (July 2015) Authors: Kempen, H.; Asztalos, B.F.; Jeyarajah, E.; Otvos, J.; Gomaraschi, M.; Calabresi, L.; Kallend, D.; Bobillier, A.; Bellibas, S.; Wijngaard, P. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e66 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗